Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $220.3 million.

  • Aclaris Therapeutics' Liabilities and Shareholders Equity fell 3.76% to $175.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $783.1 million, marking a year-over-year increase of 9.53%. This contributed to the annual value of $220.3 million for FY2024, which is 11.61% up from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Liabilities and Shareholders Equity is $220.3 million, which was up 11.61% from $197.4 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Liabilities and Shareholders Equity registered a high of $254.6 million during FY2022, and its lowest value of $70.8 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $224.1 million, with a median of $220.3 million in 2024.
  • Per our database at Business Quant, Aclaris Therapeutics' Liabilities and Shareholders Equity declined by 27.99% in 2020 and then surged by 254.90% in 2021.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Liabilities and Shareholders Equity stood at $70.8 million in 2020, then skyrocketed by 254.90% to $251.2 million in 2021, then grew by 1.35% to $254.6 million in 2022, then fell by 22.46% to $197.4 million in 2023, then rose by 11.61% to $220.3 million in 2024.